|View printer-friendly version|
Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver Congress™
*Results from full 24 weeks of dosing from the first two cohorts of Part A in the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted in oral and poster presentations
*30% of patients in first two cohorts achieved >0.5log10 reduction in HBsAg
*Additional benefit of >0.5log10 reduction in HBsAg observed in HBeAg high viral load patients when sequentially-dosed with tenofovir disoproxil fumarate
*Dose and exposure-dependent effect of inarigivir on HBV DNA and HBV RNA demonstrated
In the poster presentation, Professor
“The first two cohorts have demonstrated a dose and exposure-dependent effect of inarigivir on HBV DNA and HBV RNA, which is enhanced in HBeAg-negative patients and those with initial low baseline levels of HBsAg and HBV DNA,” said Professor Yuen. “Of further interest, 9 of the 30 patients (30%) had reductions in HBsAg of >0.5 log10, an effect not seen with nucleotides or other oral agents currently under development and that is indicative of the potential for functional cure.”
In the oral presentation, Professor
Professor Locarnini stated, “An HBsAb antibody response is needed for immunological viral cure. These findings at low doses of inarigivir are rarely seen (<2%) with nucleotide/nucleosides and reflect the novel direct acting anti-viral activity of inarigivir and the potential for RIG-I activation to drive T follicular helper (TFH) cell formation and development of an anti-viral antibody response. We look forward to the future examination of the data from the ongoing dose escalation and combination studies.”
Additional details, including presentation abstracts, can be found on the ILC website at https://ilc-congress.eu/. A copy of the presentation materials can be accessed by visiting the Presentations and Publications section of the
About Inarigivir and the ACHIEVE Trial
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary data that
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date after the date hereof.
For investor and media inquiries:
Source: Spring Bank Pharmaceuticals, Inc.